Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Skin Res Technol. 2024 Jun;30(6):e13766. doi: 10.1111/srt.13766.
Severe acne breakouts often lead to atrophic acne scars, which affect millions of people worldwide and can significantly affect a person's self-confidence and self-image. Given the difficulty in treating atrophic acne scars, this study aims to investigate the efficacy of topical phenytoin in the treatment of atrophic acne scars.
This split face clinical trial on 25 patients between the ages of 18 and 40 involved the application of microneedling on one side of the face, with three sessions taking place over the course of a month. On the other side, a 1% phenytoin cream was administered three times daily for 1 week following the microneedling procedure. Baseline information was collected for all patients, and follow-up assessments were conducted during the treatment sessions and 2 months after the last session. The assessments included evaluating the number and area of pores and spots, determining scar severity, assessing patient satisfaction, and recording any potential complications.
Among patients, 20 individuals (80%) were females, and the average age of the participants was 35.96 ± 9.23. In terms of the fine pore area, despite the fine pore count, both groups showed improvement over time (p: 0.03 vs. 0.06). Also, regarding large pore count and area, and the count and area of spots, both groups showed improvement over time (p: 0.001). However, there were no significant differences between the two groups (p > 0.05). On the other hand, when it comes to acne scar grade and patients' satisfaction, the phenytoin group outperformed the control group in all follow-up sessions and this difference was found to be significant (p: 0.001). It is worth noting that no complications were observed among any of the patients.
It appears that combining phenytoin cream with microneedling has a more effective therapeutic outcome in enhancing atrophic acne scars, when compared to microneedling alone, and this method can be regarded as a viable alternative in treating these types of scars.
严重的痤疮爆发常常导致萎缩性痤疮疤痕,影响了全球数以百万计的人,并可能严重影响一个人的自信和自我形象。鉴于治疗萎缩性痤疮疤痕的难度,本研究旨在探讨局部苯妥英钠治疗萎缩性痤疮疤痕的疗效。
这项针对 25 名年龄在 18 至 40 岁之间的患者的分面临床试验涉及在面部一侧进行微针治疗,共进行三次,每次治疗间隔一个月。在另一侧,在微针治疗后一周内,每天三次给予 1%苯妥英钠乳膏。所有患者均收集基线信息,并在治疗期间和最后一次治疗后 2 个月进行随访评估。评估包括评估毛孔和斑点的数量和面积,确定疤痕严重程度,评估患者满意度,并记录任何潜在的并发症。
在患者中,20 名(80%)为女性,参与者的平均年龄为 35.96±9.23。就细孔面积而言,尽管细孔计数,但两组均随时间推移而改善(p:0.03 与 0.06)。此外,关于大毛孔计数和面积以及斑点计数和面积,两组均随时间推移而改善(p:0.001)。然而,两组之间没有显著差异(p>0.05)。另一方面,就痤疮疤痕等级和患者满意度而言,苯妥英钠组在所有随访中均优于对照组,且这种差异具有统计学意义(p:0.001)。值得注意的是,所有患者均未观察到并发症。
与单独使用微针治疗相比,将苯妥英钠乳膏与微针治疗相结合似乎在改善萎缩性痤疮疤痕方面具有更有效的治疗效果,这种方法可作为治疗此类疤痕的一种可行选择。